News
20/04/2021

Industry association reports Germany continues to be pharma innovator

The German chemical industry association, the Verband der Chemischen Industrie, VCI, has published figures showing Germany’s chemical and pharmaceutical industries are groundbreaking in terms of national and international research and development (R&D). The report shows that for some years now, the sector has been investing more than six percent of its turnovers in R&D.

Pillenproduktion in der pharmazeutischen Industrie; Quelle: istockphoto.com/zorazhuang
© istock.com/zorazhuang

Statistics indicate that in 2019, the chemical and pharmaceutical industries together dedicated EUR thirteen billion to R&D, with pharma accounting for around 62 percent of that total. The VCI notes that within R&D, contract research plays a key role, especially in the drug industry.

In this area, figures showed that 33 percent of pharmaceuticals R&D was done on contract with external companies. Meanwhile, the VCI also reported that the sectors together accounted for some 15 percent of all German processing industry spending on domestic R&D in 2018, meaning only the automobile and electronics industries had greater shares. The VCI report furthermore notes that well over half of the companies in Germany’s pharma sector, 68 percent, had permanent departments dedicated to innovative development in 2018.

The VCI says the sector’s dedication to research and its R&D expenditure have helped place Germany in the top-five in the 2020 Innovation Indicator ranking of the world’s 35 most innovative industrialized countries. The VCI notes that in the past two decades, the country has moved up six places, as is now ranked only after Switzerland, Singapore, and Belgium.

In addition to the VCI, the export initiative for the German Healthcare Industry, HEALTH MADE IN GERMANY, is another place to learn more about innovation and contract research in German pharmaceuticals and healthcare. The initiative has published a series of informative industry profiles, including those on the pharmaceuticals sector and contract research.